A clinical-stage topical non-opioid analgesic designed to deliver rapid onset and sustained local pain relief from a single application — without systemic exposure, opioid risk, or the duration limitations of existing topical anesthetics.
AAI-201 is a mutual prodrug — a single molecule that cleaves into two therapeutically active agents at the site of application, delivering both immediate anesthesia and sustained anti-inflammatory action.
Thermosensitive gel is liquid at room temperature for precise application. On contact with skin at 32°C, it transitions to a bioadhesive gel matrix that anchors the drug directly at the injury site.
2–3× faster penetration vs EMLAThe mutual prodrug bond breaks at physiological conditions, releasing lidocaine for immediate local anesthesia and naringenin-7-O-hemisuccinate for sustained anti-inflammatory, wound healing, and angiogenesis-promoting activity.
Dual-action · Single moleculeThe gel depot sustains controlled release directly at the wound. Continuous analgesia for up to 12 hours from a single application — eliminating the gap where opioid prescriptions typically begin.
Sustained local releaseAAI-201's delivery system is a thermosensitive gel matrix — liquid at room temperature for easy application, solid on skin contact. This phase transition creates a bioadhesive depot that locks the active compound at the wound site for sustained, controlled release.
AAI-201 demonstrated statistically significant pain reduction in a randomized, controlled trial — with an exceptional safety profile across 7,000+ patients.
Seven years of clinical use produced a safety record that is designed to be a significant differentiator in regulatory discussions and commercial positioning.
Across 7,000+ patients treated between 2012 and 2019. No drug-related hospitalizations, allergic reactions, or treatment discontinuations reported.
Breast milk transfer measured at below detection threshold. A critical differentiator for the postpartum pain indication — the lead clinical target.
The gel depot delivers the active compound directly at the wound site. No CNS depression, no respiratory risk, no addiction potential, no impairment of daily function.
AAI-201's mechanism of action — sustained local analgesia with anti-inflammatory and wound healing properties — creates potential applicability across multiple clinical settings.
Pain management following vaginal delivery — the setting validated in the published Mt. Sinai RCT. Addresses critical unmet need: safe, effective pain relief for nursing mothers.
Acute pain management following minor to moderate surgical procedures — the largest addressable market. Currently managed with lidocaine (short) or opioids (risky).
Pain management during and after dermatological interventions including biopsies, excisions, laser treatments, and cosmetic procedures.
Sustained pain relief combined with wound-healing promotion for chronic wound patients — leveraging AAI-201's demonstrated angiogenesis and collagen modulation properties.
The mutual prodrug molecule itself
Mutual prodrug design and synthesis methodology
Thermosensitive gel matrix and sustained-release delivery
Transdermal delivery and depot formation technology
Methods of treatment for specific pain indications
Generative models for mutual prodrug candidate design trained on proprietary clinical data
RWE-informed system for predicting skin penetration and sustained-release profiles
Predicting thermosensitive gel phase-transition and depot behavior from molecular structure
Adverse event risk scoring including breast milk transfer from patient-level RWE
Five pharma patent applications covering the drug. Four AI patent applications covering the platform. All prosecution-ready. The combination of drug composition, formulation, delivery, and AI method claims is designed to create comprehensive protection across both assets.
AAI-201 targets prescribers already using inferior products — with a fundamentally superior mechanism and broader indication potential.
Analgesia AI is advancing AAI-201 toward the Phase 2a study and seeking strategic partners and investors to support this critical clinical milestone.
This page contains forward-looking statements regarding the development and commercialization potential of AAI-201. These statements reflect management's current expectations and involve known and unknown risks and uncertainties. Actual results may differ materially. Clinical data presented is from a published study and real-world use; these results may not be predictive of outcomes in future clinical trials. Market comparables are provided for contextual reference and should not be interpreted as projections of the company's future revenue. "First-in-class" refers to the company's belief that no other marketed product combines a mutual prodrug mechanism with a thermosensitive topical delivery system for sustained non-opioid analgesia. Nothing on this page constitutes an offer to sell or solicitation of an offer to buy securities. Patent protections are subject to applicable examination processes and jurisdictional laws. © 2026 Analgesia AI Ltd. All rights reserved.